Metronidazole Safety in Pregnancy
Metronidazole is safe to use after the first trimester of pregnancy, but should be avoided during the first trimester unless absolutely necessary for serious infections where no alternatives exist.
First Trimester: Avoid Unless Critical
The FDA drug label explicitly states that metronidazole is contraindicated in the first trimester for trichomoniasis 1. While the drug is classified as Pregnancy Category B (animal studies show no harm, but adequate human studies are lacking), the FDA label emphasizes that "use of metronidazole for trichomoniasis in the first trimester of pregnancy should be carefully evaluated because metronidazole crosses the placental barrier and its effects on human fetal organogenesis are not known" 1.
Evidence on First Trimester Safety:
Teratogenicity: Multiple meta-analyses show no increased risk of major congenital malformations. A 1995 meta-analysis of 7 studies found an odds ratio of 0.93 (95% CI 0.73-1.18) for birth defects with first-trimester exposure 2. A 2012 cohort study of 2,829 pregnancies found no association between first-trimester metronidazole and congenital anomalies (OR 0.86,95% CI 0.30-2.45) 3.
Spontaneous abortion concern: A 2021 systematic review found a pooled OR of 1.72 (95% CI 1.40-2.12) for spontaneous abortion 4. However, this association is confounded by the severity of underlying genitourinary infections, which themselves increase miscarriage risk 5. The causality remains uncertain.
Specific malformation: One meta-analysis identified a potential signal for congenital hydrocephaly (OR 4.06,95% CI 1.75-9.42) 4, though this requires confirmation in larger studies.
Second and Third Trimesters: Safe and Recommended
After the first trimester, metronidazole can be used safely 6. The 1993 CDC guidelines explicitly state: "Patients may be treated after the first trimester with 2 g of metronidazole in a single dose" for trichomoniasis 6.
For bacterial vaginosis in pregnancy, the 2002 CDC guidelines recommend:
- Metronidazole 250 mg orally three times daily for 7 days as the preferred regimen 7
- Alternative: Clindamycin 300 mg orally twice daily for 7 days
Clinical Context:
The rationale for using metronidazole in later pregnancy includes:
- Preventing adverse outcomes: Untreated bacterial vaginosis and trichomoniasis are associated with premature rupture of membranes, preterm labor, and preterm delivery 6, 7
- No evidence of harm: Studies show no association with preterm birth (RR 1.02,95% CI 0.80-1.32), low birth weight (OR 1.05,95% CI 0.77-1.43), or malformations when used in second/third trimesters 3
Important Caveats
Avoid high-dose, short-duration regimens in high-risk pregnancies: A 2021 meta-analysis found that treatment duration ≤3 days among women with previous preterm delivery was associated with increased preterm birth (RR 1.67,95% CI 1.07-2.62) 4. Use the standard 7-day regimen instead.
Lower doses preferred in pregnancy: The 2002 CDC guidelines recommend 250 mg three times daily (rather than the standard 500 mg twice daily used in non-pregnant women) to minimize fetal exposure 7.
Screening considerations: The 2008 USPSTF recommends against screening for bacterial vaginosis in low-risk pregnant women (Grade D recommendation), as treatment does not reduce adverse outcomes in this population 8. However, symptomatic women should be treated.
Practical Algorithm
First Trimester:
- Avoid metronidazole for trichomoniasis or bacterial vaginosis unless infection is severe and no alternatives exist
- If treatment is absolutely necessary, use after careful risk-benefit discussion with the patient
- Consider clindamycin vaginal cream as alternative for bacterial vaginosis 6
Second/Third Trimester:
- Use metronidazole 250 mg orally three times daily for 7 days for bacterial vaginosis
- Use metronidazole 2 g single dose for trichomoniasis
- Avoid short-duration (≤3 days) high-dose regimens in women with prior preterm delivery
The key principle: weigh the documented risks of untreated infection (preterm delivery, membrane rupture) against the theoretical but unproven risks of first-trimester exposure, and the well-established safety profile after the first trimester.